Table IV.
Incidence of recurrence, diagnosis, and approach
| BCC 4,402 (84.2) | SCC 371 (7.1) | |
|---|---|---|
| Patient-years follow-up, n (%) | 12,111 | 915 |
| Average follow-up time, years, mean (SD) | 2.8 (1.6) | 2.5 (1.6) |
| Patients lost to follow-up prior to recurrence, n (%) | 688 (15.6) | 45 (12.1) |
| Deaths, n (%) | 155 (3.5) | 47 (12.7) |
| Recurrences, n (%) | 154 (3.5) | 41 (11.1) |
| All tumoursa | 1.3 (1.1–1.5) | 4.5 (3.3–6.1) |
| Primary tumoursa | 0.9 (0.7–1.2) | 3.2 (2.0–5.1) |
| Recurrent tumoursa | 1.8 (1.4–2.4) | 7.7 (4.6–13.1) |
| Persistent tumoursa | 2.0 (1.4–2.7) | 5.1 (2.7–9.4) |
| Number of recurrences | ||
| 1 | 136 (88) | 33 (80) |
| 2 | 13 (8) | 7 (17) |
| 3 or more | 5 (2) | 1 (2) |
| Diagnosis | ||
| Clinical | 21 (25) | 8 (36) |
| Histological | 63 (75) | 14 (64) |
| Treatment | ||
| Re-intervention | 116 (75) | 24 (59) |
| Radiotherapy | 10 (6) | 10 (24) |
| Chemotherapy | 1 (0.7) | NA |
| Hedgehog inhibitors | 6 (4) | NA |
| Tyrosine kinase inhibitors | 2 (1.3) | NA |
| Other options | 17 (11) | 5 (12) |
| Palliative care | 2 (1.3) | 2 (5) |
a
Incidence per 100 person-years 95% confidence interval.
BCC: basal cell carcinoma; SCC: squamous cell carcinoma; NA: non-applicable.